Last reviewed · How we verify
fibrinogen concentrate
At a glance
| Generic name | fibrinogen concentrate |
|---|---|
| Also known as | Haemocomplettan P, ATC code: B02B B01, Riastap, Haemocompletan, Haemocomplettan, CSL Behring |
| Sponsor | Hongjia Zhang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery (PHASE3)
- Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients (PHASE4)
- Fibrinogen Early In Severe Trauma StudY II (PHASE3)
- Administration of Fibrinogen Concentrate for Refractory Bleeding (PHASE2)
- Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment. (NA)
- Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery (PHASE4)
- Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency (PHASE3)
- Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fibrinogen concentrate CI brief — competitive landscape report
- fibrinogen concentrate updates RSS · CI watch RSS
- Hongjia Zhang portfolio CI